AstraZeneca’s (AZN) Calquence in combination with venetoclax has been approved in the U.S. by the FDA as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Calquence with venetoclax approved in U.S. by FDA
- AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
- AstraZeneca Pauses Real‑World NMOSD Study in Russia, Keeping Near‑Term Stock Impact Limited
- AstraZeneca’s Calquence Japan Safety Study Wraps Up, Clarifying Real-World Risk for AZN Investors
- AstraZeneca marketing authorization application for Enhertu validated by EMA